These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 24211169

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The Modified Surface Killing Assay Distinguishes between Protective and Nonprotective Antibodies to PspA.
    Genschmer KR, Vadesilho CFM, McDaniel LS, Park SS, Hale Y, Miyaji EN, Briles DE.
    mSphere; 2019 Dec 11; 4(6):. PubMed ID: 31826968
    [Abstract] [Full Text] [Related]

  • 3. Establishment of a modified opsonophagocytic killing assay for anti-pneumococcal surface protein A antibody.
    Kuroda E, Koizumi Y, Piao Z, Nakayama H, Tomono K, Oishi K, Hamaguchi S, Akeda Y.
    J Microbiol Methods; 2023 Sep 11; 212():106804. PubMed ID: 37543109
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae.
    Gor DO, Ding X, Briles DE, Jacobs MR, Greenspan NS.
    Infect Immun; 2005 Mar 11; 73(3):1304-12. PubMed ID: 15731027
    [Abstract] [Full Text] [Related]

  • 6. Pneumococcal surface protein A is expressed in vivo, and antibodies to PspA are effective for therapy in a murine model of pneumococcal sepsis.
    Swiatlo E, King J, Nabors GS, Mathews B, Briles DE.
    Infect Immun; 2003 Dec 11; 71(12):7149-53. PubMed ID: 14638806
    [Abstract] [Full Text] [Related]

  • 7. Correlation between in vitro complement deposition and passive mouse protection of anti-pneumococcal surface protein A monoclonal antibodies.
    Khan N, Qadri RA, Sehgal D.
    Clin Vaccine Immunol; 2015 Jan 11; 22(1):99-107. PubMed ID: 25410204
    [Abstract] [Full Text] [Related]

  • 8. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.
    Nguyen CT, Kim SY, Kim MS, Lee SE, Rhee JH.
    Vaccine; 2011 Aug 05; 29(34):5731-9. PubMed ID: 21696869
    [Abstract] [Full Text] [Related]

  • 9. Genetic immunization with the region encoding the alpha-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae.
    Bosarge JR, Watt JM, McDaniel DO, Swiatlo E, McDaniel LS.
    Infect Immun; 2001 Sep 05; 69(9):5456-63. PubMed ID: 11500417
    [Abstract] [Full Text] [Related]

  • 10. The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis.
    Daniels CC, Coan P, King J, Hale J, Benton KA, Briles DE, Hollingshead SK.
    Infect Immun; 2010 May 05; 78(5):2163-72. PubMed ID: 20194601
    [Abstract] [Full Text] [Related]

  • 11. Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.
    da Silva MA, Converso TR, Gonçalves VM, Leite LCC, Tanizaki MM, Barazzone GC.
    Clin Vaccine Immunol; 2017 Aug 05; 24(8):. PubMed ID: 28637805
    [Abstract] [Full Text] [Related]

  • 12. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses.
    Miyaji EN, Dias WO, Tanizaki MM, Leite LC.
    FEMS Immunol Med Microbiol; 2003 Jun 10; 37(1):53-7. PubMed ID: 12770760
    [Abstract] [Full Text] [Related]

  • 13. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
    Bitsaktsis C, Iglesias BV, Li Y, Colino J, Snapper CM, Hollingshead SK, Pham G, Gosselin DR, Gosselin EJ.
    Infect Immun; 2012 Mar 10; 80(3):1166-80. PubMed ID: 22158740
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells.
    Goulart C, Darrieux M, Rodriguez D, Pimenta FC, Brandileone MC, de Andrade AL, Leite LC.
    Vaccine; 2011 Feb 11; 29(8):1634-42. PubMed ID: 21211592
    [Abstract] [Full Text] [Related]

  • 20. Rational selection of broadly cross-reactive family 2 PspA molecules for inclusion in chimeric pneumococcal vaccines.
    Converso TR, Goulart C, Rodriguez D, Darrieux M, Leite LCC.
    Microb Pathog; 2017 Aug 11; 109():233-238. PubMed ID: 28602840
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.